Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

Vertex Pharma has chosen the three-drug combination ... advocacy since triple results were released,” he said. “I find it very hard to believe that there's going to be governments [denying ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Current price $500.02 52-week high $519.88 ...

Let's take a closer look. The post Is a New AI Model the Catalyst Alphabet Stock Needed? appeared first on The Motley Fool ...